These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

568 related items for PubMed ID: 22411425

  • 1. Dipeptidyl peptidase-4 inhibitors in the elderly: more benefits or risks?
    Paolisso G, Monami M, Marfella R, Rizzo MR, Mannucci E.
    Adv Ther; 2012 Mar; 29(3):218-33. PubMed ID: 22411425
    [Abstract] [Full Text] [Related]

  • 2. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
    Neumiller JJ.
    J Am Pharm Assoc (2003); 2009 Mar; 49 Suppl 1():S16-29. PubMed ID: 19801361
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Incretin therapies in the management of elderly patients with type 2 diabetes mellitus.
    Bourdel-Marchasson I, Schweizer A, Dejager S.
    Hosp Pract (1995); 2011 Feb; 39(1):7-21. PubMed ID: 21441754
    [Abstract] [Full Text] [Related]

  • 5. Complementing insulin therapy to achieve glycemic control.
    Barnett AH.
    Adv Ther; 2013 Jun; 30(6):557-76. PubMed ID: 23797471
    [Abstract] [Full Text] [Related]

  • 6. GLP-1 agonists and dipeptidyl-peptidase IV inhibitors.
    Gallwitz B.
    Handb Exp Pharmacol; 2011 Jun; (203):53-74. PubMed ID: 21484567
    [Abstract] [Full Text] [Related]

  • 7. Newly approved and promising antidiabetic agents.
    Combettes M, Kargar C.
    Therapie; 2007 Jun; 62(4):293-310. PubMed ID: 17983555
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Second line therapy: type 2 diabetic subjects failing on metformin GLP-1/DPP-IV inhibitors versus sulphonylurea/insulin: for GLP-1/DPP-IV inhibitors.
    Kumar A.
    Diabetes Metab Res Rev; 2012 Dec; 28 Suppl 2():21-5. PubMed ID: 23280862
    [Abstract] [Full Text] [Related]

  • 10. Role of vildagliptin in managing type 2 diabetes mellitus in the elderly.
    Halimi S, Raccah D, Schweizer A, Dejager S.
    Curr Med Res Opin; 2010 Jul; 26(7):1647-56. PubMed ID: 20441397
    [Abstract] [Full Text] [Related]

  • 11. Pharmacotherapy of hyperglycemia.
    Kulasa KM, Henry RR.
    Expert Opin Pharmacother; 2009 Oct; 10(15):2415-32. PubMed ID: 19743938
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Combination therapy of dipeptidyl peptidase-4 inhibitors and metformin in type 2 diabetes: rationale and evidence.
    Liu Y, Hong T.
    Diabetes Obes Metab; 2014 Feb; 16(2):111-7. PubMed ID: 23668534
    [Abstract] [Full Text] [Related]

  • 14. Pharmacologic management of the older patient with type 2 diabetes mellitus.
    Neumiller JJ, Setter SM.
    Am J Geriatr Pharmacother; 2009 Dec; 7(6):324-42. PubMed ID: 20129254
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Antihyperglycaemic therapy in elderly patients with type 2 diabetes: potential role of incretin mimetics and DPP-4 inhibitors.
    Mathieu C, Bollaerts K.
    Int J Clin Pract Suppl; 2007 Aug; (154):29-37. PubMed ID: 17593275
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Significance of combination therapy with an insulin sensitizer and a DPP-4(dipeptidyl peptidase-4) inhibitor].
    Yasuda T, Shimomura I.
    Nihon Rinsho; 2013 Mar; 71(3):555-62. PubMed ID: 23631252
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Replacing SUs with incretin-based therapies for type 2 diabetes mellitus: challenges and feasibility.
    Knop FK, Holst JJ, Vilsbøll T.
    IDrugs; 2008 Jul; 11(7):497-501. PubMed ID: 18600596
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.